Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 08:35:58 +0200Thu, 23 May 2024 15:18:00 +0200Lumykras : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5522-en_3.pdfLumykras : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5522-en_3.pdfThu, 23 May 2024 15:18:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 5, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/lumykrasHuman medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 5, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/lumykrasThu, 23 May 2024 13:10:00 +0200Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Lumykras, sotorasib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0089/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002690-pip02-22Opinion/decision on a Paediatric investigation plan (PIP): Lumykras, sotorasib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0089/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002690-pip02-22Fri, 05 Apr 2024 11:44:31 +0200Human medicine